Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MethylGene Opts for Royalties/Milestones in Celgene Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

MethylGene Opts for Royalties/Milestones in Celgene Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MethylGene, Inc. has exercised its right to convert to a royalty and milestone arrangement with Celgene Corp. for MGCD0103 under the 2006 license and collaboration agreement between the companies.
   
MethylGene will no longer be responsible for development costs for the drug. Celgene will assume all program costs for its licensed territories. MethylGene will receive royalties in lieu of profit sharing in North America and is eligible to receive milestone payments of as much as $141 million. Celgene will also pay royalties to MethylGene on annual sales in its territories. MethylGene retains its rights under the original terms of the agreement to co-develop and co-promote subsequent compounds, including second-generation histone deacetylase (HDAC) inhibitors and sirtuin inhibitors for cancer.
   
“We believe that MGCD0103 presents a promising opportunity for the treatment of cancer. After thoughtful and careful analysis conducted with outside consultants, we have concluded that converting to a royalty at this time is financially advantageous,” said Donald F. Corcoran, president and chief executive officer of MethylGene. “Moving forward, while participating in the upside and potential of MGCD0103, we will be focusing on developing the two compounds of which we own 100%, MGCD290 and MGCD265, which are expected to enter Phase I trials by the end of this year.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters